Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
21
self-reported 2–10 band
Founded
Not recorded
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
2
Post IPO equity · Apr 2024 · US$ 13.2M
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
DIMERIX LIMITED
ABN18001285230
Legal entities
Show as table · Dimerix Limited: 1 registry entity
| DIMERIX LIMITED | ABN 18001285230 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases.
Dimerix’ lead clinical asset, DMX-200 (or QYTOVRA® in some territories), is in Phase 3 trials as a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease.
Specialties
All 9 specialties
- Biotechnology
- Drug Development
- Chronic Kidney Disease
- Nephrology
- In Vitro Screening
- Platform technology
- Clinical Research
- Drug Discovery
- Diabetic Kidney Disease
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AUMelbourne, Victoria 3000Primary
Grid intelligence Members
Funding
Last round · 12 April 2024US$ 13.2MPost IPO equity
Rounds2
Round typePost IPO equity · secondary transaction
Amount (USD)13,200,000
Stage rank6
Investors named0
Since last round1 yr 9 mo
Funding
Show as table · 2 funding rounds
| Rounds | 2 |
|---|---|
| Axis | 2024 to 2026 |
| Post IPO equity · 12 Apr 2024 | US$ 13.2M |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
Which legal entity operates under Dimerix Limited?
One Victoria entity on the ABR: DIMERIX LIMITED (ABN 18 001 285 230), high confidence.
How many people work at Dimerix Limited?
21 counted staff profiles at January 2026, above the self-reported 2–10 band.
Where does Dimerix Limited have offices?
One address on record, Australia only. Primary: Melbourne, Victoria 3000.
Has Dimerix Limited raised funding?
Two rounds. Latest 12 April 2024: post IPO equity, US$13,200,000.
What does Dimerix Limited list as its specialties?
Nine tags on the brand's own list, among them clinical research, nephrology and biotechnology.
Which companies are listed alongside Dimerix Limited?
15 profiles list Dimerix Limited as a peer — 91st percentile in Pharmaceutical Manufacturing. It lists ten peers of its own. Syntara and Kinoxis Therapeutics Pty Ltd list it back.